| [1] Walsh G. Biopharmaceutical benchmarks 2014[J]. Nat Biotech, 2014, 32(10): 992－1 000.[2] European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues[OL]. London: European Medicines Agency; 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf.[3] Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product[OL]. Rockville: Food and Drug Administration; 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.[4] Berkowitz S A, Engen J R, Mazzeo J R, et al. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars[J]. Nat Rev Drug Discov, 2012, 11(7): 527－540.[5] Falconer R J, Jackson-Matthews D, Mahler S M. Analytical strategies for assessing comparability of biosimilars[J]. J Chem Technol Biotechnol, 2011, 86(7): 915－922.[6] Federici M, Lubiniecki A, Manikwar P, et al. Analytical lessons learned from selected therapeutic protein drug comparability studies[J]. Biologicals, 2013, 41(3): 131－147.[7] Houde D, Berkowitz S A, Engen J R. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies[J]. J Pharm Sci, 2011, 100(6): 2 071－2 086.[8] Amezcua C A, Szabo C M. Assessment of higher order structure comparability in therapeutic proteins using nuclear magnetic resonance spectroscopy[J]. J Pharm Sci, 2013, 102(6): 1 724－1 733.[9] Wishart D S. Characterization of biopharmaceuticals by NMR spectroscopy[J]. TrAC-Trends Anal Chem, 2013, 48: 96－111.[10] Quinternet M, Starck J P, Delsuc M A, et al. Heteronuclear NMR provides an accurate assessment of therapeutic insulin's quality[J]. J Pharm Biomed Anal, 2013, 78/79: 252－254. [11] Jin X, Kang S, Kwon H, et al. Heteronuclear NMR as a 4-in-1 analytical platform for detecting modification-specific signatures of therapeutic insulin formulations[J]. Anal Chem, 2014, 86(4): 2 050－2 056.[12] Panjwani N, Hodgson D J, Sauve S, et al. Assessment of the effects of pH, formulation and deformulation on the conformation of interferon alpha-2 by NMR[J]. J Pharm Sci, 2010, 99(8): 3 334－3 342.[13] Sauve S, Gingras G, Aubin Y. Assessment of the three-dimensional structure of recombinant protein therapeutics by NMR fingerprinting: demonstration on recombinant human granulocyte macrophage-colony stimulation factor[J]. Biomol NMR Assign, 2008, 2(1): 5－7.[14] Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar Rituximab GP2013 and originator Rituximab[J]. Biodrugs, 2013, 27(5): 495－507.[15] Vu B K, Walsh J D, Dimitrov D S, et al. Dynamics of antibody domains studied by solution NMR[J]. Methods Mol Biol, 2009, 525:533－543, xv. [16] Poppe L, Jordan J B, Lawson K, et al. Profiling formulated monoclonal antibodies by 1H NMR spectroscopy[J]. Anal Chem, 2013, 85(20): 9 623－9 629. |
